These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 36315910)
21. Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease. Tchernychev B; Li H; Lee SK; Gao X; Ramanarasimhaiah R; Liu G; Hall KC; Bernier SG; Jones JE; Feil S; Feil R; Buys ES; Graul RM; Frenette PS; Masferrer JL Br J Pharmacol; 2021 Sep; 178(17):3463-3475. PubMed ID: 33864386 [TBL] [Abstract][Full Text] [Related]
22. Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation. Keleku-Lukwete N; Suzuki M; Otsuki A; Tsuchida K; Katayama S; Hayashi M; Naganuma E; Moriguchi T; Tanabe O; Engel JD; Imaizumi M; Yamamoto M Proc Natl Acad Sci U S A; 2015 Sep; 112(39):12169-74. PubMed ID: 26371321 [TBL] [Abstract][Full Text] [Related]
26. The gut microbiome in sickle cell disease: Characterization and potential implications. Brim H; Taylor J; Abbas M; Vilmenay K; Daremipouran M; Varma S; Lee E; Pace B; Song-Naba WL; Gupta K; Nekhai S; O'Neil P; Ashktorab H PLoS One; 2021; 16(8):e0255956. PubMed ID: 34432825 [TBL] [Abstract][Full Text] [Related]
27. Circadian period 2: a missing beneficial factor in sickle cell disease by lowering pulmonary inflammation, iron overload, and mortality. Adebiyi MG; Zhao Z; Ye Y; Manalo J; Hong Y; Lee CC; Xian W; McKeon F; Culp-Hill R; D' Alessandro A; Kellems RE; Yoo SH; Han L; Xia Y FASEB J; 2019 Sep; 33(9):10528-10537. PubMed ID: 31260634 [TBL] [Abstract][Full Text] [Related]
28. End Organ Affection in Sickle Cell Disease. Bathla T; Lotfollahzadeh S; Quisel M; Mehta M; Malikova M; Chitalia VC Cells; 2024 May; 13(11):. PubMed ID: 38891066 [TBL] [Abstract][Full Text] [Related]
30. Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease. Rossato P; Federti E; Matte A; Glantschnig H; Canneva F; Schuster M; Coulibaly S; Schrenk G; Voelkel D; Dockal M; Plaimauer B; Andolfo I; Iolascon A; Rottensteiner H; Gritsch H; Scheiflinger F; Hoellriegl W; Franceschi L Haematologica; 2022 Nov; 107(11):2650-2660. PubMed ID: 35443560 [TBL] [Abstract][Full Text] [Related]
31. [Cardiac complications of sickle cell disease in children]. Astadicko I; Dresse MF; Seghaye MC Rev Med Liege; 2018 Nov; 73(11):550-556. PubMed ID: 30431243 [TBL] [Abstract][Full Text] [Related]
32. Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates. Novelli EM; Kato GJ; Ragni MV; Zhang Y; Hildesheim ME; Nouraie M; Barge S; Meyer MP; Hassett AC; Gordeuk VR; Gladwin MT; Isenberg JS Am J Hematol; 2012 Mar; 87(3):326-30. PubMed ID: 22318901 [TBL] [Abstract][Full Text] [Related]
33. Acute and chronic pain management in patients with sickle cell disease in the modern era: a comprehensive review. Tolu SS; Van Doren L Transfus Apher Sci; 2022 Oct; 61(5):103533. PubMed ID: 36058780 [TBL] [Abstract][Full Text] [Related]
34. MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease. Belcher JD; Nguyen J; Chen C; Abdulla F; Conglin R; Ivy ZK; Cummings J; Dudler T; Vercellotti GM Transl Res; 2022 Nov; 249():1-12. PubMed ID: 35878790 [TBL] [Abstract][Full Text] [Related]
38. HIV-1 infection in sickle cell disease and sickle cell trait: role of iron and innate response. Nekhai S; Kumari N Expert Rev Hematol; 2022 Mar; 15(3):253-263. PubMed ID: 35322747 [TBL] [Abstract][Full Text] [Related]
39. The role of blood rheology in sickle cell disease. Connes P; Alexy T; Detterich J; Romana M; Hardy-Dessources MD; Ballas SK Blood Rev; 2016 Mar; 30(2):111-8. PubMed ID: 26341565 [TBL] [Abstract][Full Text] [Related]